A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer (RAP)
This study is currently recruiting participants.
Verified January 2013 by Duke University
Sponsor:
Gordana Vlahovic
Collaborators:
Amgen
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Gordana Vlahovic, Duke University Medical Center
ClinicalTrials.gov Identifier:
NCT01061788
First received: February 2, 2010
Last updated: January 2, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | April 2014 |
| Estimated Primary Completion Date: | April 2013 (Final data collection date for primary outcome measure) |